Physician profile
David M Visokey
NPI 1912979261
$12,999.52
in general payments reported to CMS, 2019-2025
45 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,355 · 2020: $1,530 · 2021: $1,519 · 2022: $1,564 · 2023: $1,791 · 2024: $1,910 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,021 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,020.50 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,669.13 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,494.64 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,465.75 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $713.98 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $516.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $504.19 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Harmony Biosciences LLC | $444.44 | 2020-2024 | Wakix |
| Axsome Therapeutics, INC. | $417.83 | 2023-2025 | Sunosi |
| Insmed, INC. | $402.50 | 2021-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $384.01 | 2019-2020 | |
| Mylan Specialty L.P. | $331.27 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $276.61 | 2019-2025 | Dupixent |
| Electromed, INC. | $215.46 | 2019-2024 | Smartvest |
| Jazz Pharmaceuticals INC. | $195.41 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $176.27 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $151.77 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Viatris Specialty LLC | $148.37 | 2025 | Yupelri |
| United Therapeutics Corporation | $147.53 | 2019-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $137.17 | 2021-2025 | Glassia, Cuvitru, Hyqvia |
| Abbvie INC. | $101.32 | 2021-2025 | Teflaro |
| Amgen INC. | $89.07 | 2022-2025 | Tezspire, Tavneos |
| Verona Pharma, INC. | $87.85 | 2025 | Ohtuvayre |
| Allergan, INC. | $84.60 | 2019-2020 | |
| Intuitive Surgical, INC. | $79.78 | 2025 | |
| Gilead Sciences, INC. | $66.74 | 2021-2023 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $62.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $61.89 | 2019-2025 | |
| Genentech USA, INC. | $57.29 | 2019 | |
| Philips North America LLC | $54.17 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $45.06 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $43.80 | 2023-2025 | Lumryz |
| Astellas Pharma US INC | $42.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.08 | 2020-2022 | |
| Pfizer INC. | $35.52 | 2023-2025 | |
| Pulmonx Corporation | $35.27 | 2022 | |
| Advanced Respiratory, INC | $34.41 | 2020-2021 | |
| Olympus America INC. | $33.81 | 2021-2023 | Visera Tracheal Intubation Videoscope |
| Itamar Medical INC | $31.80 | 2022 | |
| Shire North American Group INC | $21.94 | 2019 | |
| La Jolla Pharmaceutical Company | $21.37 | 2025 | Zevtera |
| Lilly USA, LLC | $18.12 | 2025 | Zepbound |
| Resmed Corp | $17.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.91 | 2022 | |
| Veran Medical Technologies, INC. | $12.55 | 2019 | |
| Circassia INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Visokey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.